The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Tafasitamab plus lenalidomide post-CD19 CAR-T is associated with poor outcomes in LBCL
Vincent Camus, MD, PhD, University of Rouen, Rouen, France, discusses outcomes for patients with large B-cell lymphoma (LBCL) who are treated with tafasitamab plus lenalidomide following CD19-targeting CAR-T therapy. The study found poor outcomes with short progression-free survival (PFS). Comparisons with other post-CD19 CAR-T treatments showed no significant differences in outcomes. However, patients who relapsed more than six months post-CAR-T therapy experienced slightly improved outcomes. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Incyte, AbbVie, Astra Zeneca, BMS, Ideogen, Janssen, Kiowa Kirin, Kite/Gilead, Lilly, Novartis, Octapharma, Pfizer, Pierre Fabre, Sanofi, Takeda.
